CIDRI-Africa

Image of scientist holding up a Petri dish

Supporting Excellence

The Wellcome Centre for Infectious Diseases Research in Africa fosters investigator-led approaches via the overarching scientific objective of combatting infection, especially HIV-1 and tuberculosis, through clinical and laboratory research.

Macrophages infected with M. tuberculosis; image by Dr Suraj Parihar

Basic Science

Our Basic Science Platform provides the laboratory infrastructure and technical support to ensure the safe handling of infectious material.

Subgraph of the ANIMA network for dataset HIVsetB

Biomedical Data Integration

We work with multidimensional clinical and scientific data at the molecular, cellular, clinical and population levels.

Image of a researcher and study participant reading an informed consent document

Clinical Research

CIDRI-Africa supports clinical studies in the community at our facility at Site B in Khayelitsha.

News

Wednesday, 19 December 2018

Prednisone reduces risk of TB-IRIS during antiretroviral treatment, shows CIDRI-Africa team

The PredART study—published in the New England Journal of Medicine—showed that a four-week course of moderate dose prednisone reduced the risk of TB-IRIS by 30% in HIV-positive patients at high risk.

Publication Date:

Thu, 15 Nov 2018 - 08:00

'Lung: pulmonary tuberculosis' . Credit: Wellcome Collection. CC0

Candidate tuberculosis (TB) vaccine can prevent active pulmonary TB in HIV-negative adults in phase II study

Primary analysis published in the New England Journal of Medicine shows positive results in clinical trial conducted in tuberculosis endemic regions.

Publication Date:

Tue, 25 Sep 2018 - 12:30

Icon made from <a href="http://www.onlinewebfonts.com/icon">Icon Fonts</a> is licensed by CC BY 3.0

TB meningitis clinical trial stakeholder engagement

Community stakeholders representing various Khayelitsha-based organisations gathered to consult with CIDRI-Africa’s clinical research team on future tuberculous meningitis research.

Publication Date:

Thu, 15 Nov 2018 - 11:45